Current Report Filing (8-k)
December 22 2020 - 9:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
December 22, 2020
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as
specified in its charter)
DELAWARE
|
|
41-1505029
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
|
29 Emmons Drive,
Suite B-10
Princeton, NJ
|
|
08540
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(609) 538-8200
|
(Issuer’s telephone number, including area code)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $.001 per share
|
|
SNGX
|
|
The Nasdaq Capital Market
|
Common Stock Purchase Warrants
|
|
SNGXW
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On December 22, 2020, Soligenix, Inc. (the
“Company”) issued a press release and hosted a conference call for purposes of preliminary top-line results for its
pivotal Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE Immunity)
trial evaluating SGX942 (dusquetide) in the treatment of severe oral mucositis (SOM) in patients with head and neck cancer (HNC)
receiving chemoradiation. The press release and conference call contain forward-looking statements regarding the Company, and include
cautionary statements identifying important factors that could cause actual results to differ materially from those anticipated.
The press release issued December
22, 2020 is filed herewith as Exhibit 99.1, to this Current Report on Form 8-K and a copy of the Company’s conference call
script is filed herewith as Exhibit 99.2.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Soligenix, Inc.
|
|
|
December 22, 2020
|
By:
|
/s/ Christopher J. Schaber
|
|
|
Christopher J. Schaber, Ph.D.
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
2
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Sep 2023 to Sep 2024